

1. **YY Yang**, SL Hsieh, PC Lee, YC Yeh, KC Lee, YC Hsieh, YW Wang, TY Lee, YH Huang, CC Chan, HC Lin. Long-term cannabinoid type 2 receptor agonist therapy decreases Bacterial Translocation In Rats with cirrhosis and ascites. *J Hepatol* 2014;61(5):1004-13.
2. **Ying-Ying Yang**, Tung-Hu Tsai, Yi-Tsau Huang, Tzung-Yan Lee, Che-Chang Chan, Kuei-Chuan Lee, Han-Chieh Lin. Hepatic Endothelin-1 and Endocannabinoids-Dependent Effects of Hyperleptinaemia in Nonalcoholic Steatohepatitis-Cirrhotic Rats. *Hepatology* 2012; 55: 1540-50.
3. Han-Chieh Lin, Ying-Ying Yang, Tung-Hu Tsai, Chih-Ming Huang, Yi-Tsau Huang, Fa-Yauh Lee, Tze-Tze Liu, Shou-Dong Lee. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. *J Hepatol* 2011;45:1145-53.
4. **Yang YY**, Liu HQ, Nam SW, Kunos G, Lee SS. Mechanisms of TNF α -induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNF α and endocannabinoids. *J Hepatol* 2010;53(2):298-306.
5. **YY Yang**, HC Lin, WP Lee, CJ Chu, MW Lin, FY Lee, MC Hou, JS Jap, SD Lee Association of the G-protein and alpha-2 adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of effects of diuretics in cirrhotic patients with refractory ascites: a randomized clinical trial. *Gut* 2010;59:1545-53.
6. **Ying-Ying Yang**, Kuei-Chuan Lee, Yi-Tsau Huang, Ying-Wen Wang, Ming-Chih Hou, Fa-Yauh Lee, Han-Chieh Lin, Shou-Dong Lee. Effects of N-acetylcysteine administration in hepatic microcirculation of rats with biliary cirrhosis. *J Hepatol* 2008;49(1):25-33.
7. **Ying-Ying Yang**, Han-Chieh Lin, Yi-Tsau Huang, Ming-Chih Hou, Fa-Yauh Lee, Full-Young Chang, Shou-Dong Lee. Inhibition of glucagon improves splanchnic hyporesponse to terlipressin in cirrhotic rats with blood retention in the gastric lumen. *J Hepatol* 2005;42:652-8.
8. **Ying-Ying Yang**, Han-Chieh Lin, Yi-Tsau Huang, Tzung-Yen Lee, Ming-Chih Hou, Fa-Yauh Lee, Ren-Shyan Liu, Full-Young Chang, Shou-Dong Lee. Effect of one-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. *J Hepatol* 2002;36:600-6.
9. YH Lin, NR Kuo, HC Shen, YC Chang, Roger Lin, TL Liao, HY Yeh*, YY Yang*, MC Hou, HC Lin. Prediction models combining zonulin, LPS, and LBP predict acute kidney injury and hepatorenal syndrome—acute kidney injury in cirrhotic patients. *Scientific Reports* 2023, August 4 (accepted).
10. Nai-Rong Kuo, Ming-Chih Hou*, Wei-Chi Chu, **Ying-Ying Yang***, Chia-Chang Huang, Tzu-Hao Li, Tzung-Yan Lee, Chih-Wei Liu, Tsai-Ling Liao, Shie-Liang Hsieh, Han-Chieh Lin*. Low lymphocyte-to-monocyte ratio, calcitriol level and CD206 level predict the development of ACLF in cirrhotic patients with acute decompensation. *JCMA* 2023;86(3):265-273.
11. Liu SY, Huang CC, **Yang YY***, Huang SF, Lee TY, Li TH, Hou MC, Lin HC. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice. *Plos One* 2022; 17(12): e0276717.
12. Liu Szu-Yu, Huang Chia-Chang, Shiang-Fen Huang, Tsai-Ling Liao, Nai-Rong Kuo, **Ying-Ying Yang***, Tzu-Hao Li, Chih-Wei Liu, Ming-Chih Hou, Han-Chieh Lin. Pioglitazone ameliorates acute endotoxemia-induced acute on chronic renal dysfunction in cirrhotic ascitic rats. *Cells* 2021, 10(11), 3044.
13. Hsu CF, Huang CC, Liu TT, Yang UC, Liu CW, Huang SF, **Yang YY***, Huang YH, Hou MC, Lin HC. Deletion of intestinal SIRT1 exacerbated muscle wasting in cirrhotic mice by decreasing the intestinal concentration of short-chain fatty acids and inflammation. *J Pharmacological Sciences*, 2021:147(4),

14. Yu-Lien Tsai, Chih-Wei Liu, Chien-Fu Hsu, Chia-Chang Huang, Ming-Wei Lin, Shiang-Fen Huang, Tzu-Hao Li, Kuei-Chuan Lee, Yun-Cheng Hsieh, **Ying-Ying Yang***, Tzung-Yan Lee, Hsuan-Miao Liu, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin*. Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2 α -activated COX-TXA2 pathway. *Clin Sci (Lond)*. 2020;134(15):2055-2073.
15. Hung-Cheng Tsai, Chien-Fu Hsu, Chia-Chang Huang, Shiang-Fen Huang, Tzu-Hao Li, **Ying-Ying Yang***, Ming-Wei Lin, Tzung-Yan Lee, Chih-Wei Liu, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin*. Propranolol Suppresses the T-Helper Cell Depletion-Related Immune Dysfunction in Cirrhotic Mice. *Cells* 2020, 9(3), 604.
16. Tzu-Hao Li, **Ying-Ying Yang***, Chia-Chang Huang, Chih-Wei Liu, Hung-Cheng Tsai, Ming-Wei Lin, Chang-Youh Tsai, Shiang-Fen Huang, Ying-Wen Wang, Tzung-Yan Lee, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin*. Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis. *Clin Sci (Lond)*. 2019;133(3):531-544.
17. Chih-Wei Liu, Chia-Chang Huang, Hung-Cheng Tsai, Yen-Bo Su, Shiang-Fen Huang, Kuei-Chuan Lee, Yun-Cheng Hsieh, Tzu-Hao Li, Chang-Youh Tsai, Lee-Won Chong, Shuo-Ming Ou, **Ying-Ying Yang***, Wen-Chien Fan 2, Ming-Chih Hou, Han-Chieh Lin, Shou-Dong Lee. Serum Adrenomedullin and Urinary Thromboxane B2 help Early Categorizing Acute kidney injury in De-compensated Cirrhotic Patients: a prospective cohort study. *Hep Res* 2018;48(3):E9-E21.
18. Chih-Wei Liu, Hung-Cheng Tsai, Chia-Chang Huang, Chang-Youh Tsai, Yen-Bo Su, Ming-Wei Lin, Kuei-Chuan Lee, Yun-Cheng Hsieh, Tzu-Hao Li, Shiang-Fen Huang, **Ying-Ying Yang***, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee, Shou-Dong Lee. Effects and mechanisms of caffeine to improve immunologic and metabolic abnormalities in diet-Induced obese rats. *Am J Physiol Endocrinol Metab* 2018;314(5):E433-47.
19. YB Su, TH Li, CC Huang, HC Tsai, SF Huang, YC Hsieh, YY Yang*, YH Huang, MC Hou, HC Lin. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model. *PLoS One*. 2018;13(4):e0194867.
20. HC Tsai, Tzu-Hao Li, Chia-Chang Huang, Shiang-Fen Huang, Ren-Shyan Liu, **Ying-Ying Yang***, Yun-Cheng Hsieh, Kuei-Chuan Lee, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin. Beneficial effects of the PPAR α/γ agonist aleglitazar on progressive hepatic and splanchnic abnormalities in cirrhotic rats with portal hypertension. *Am J Pathology* 2018;188(7):1608-1624.
21. WC Fan, CC Huang, **YY Yang***, A Lin, KC Lee, YC Hsieh, CP Fung, HC Hsu, MC Hou, HC Lin*. Serum pentraxin-3 and TNF-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute de-compensated cirrhotic patients. *J Micro Immunol Infect* 2017;50(6):905-914.
22. Lee PC, Yang LY, Wang YW, Huang SF, Lee KC, Hsieh YC, **Yang YY***, Hsieh SL, Hou MC, Lin HC,* Lee FY, Lee SD. Mechanisms of the prevention and inhibition of the progression and development of NASH by genetic and pharmacological DcR3 supplementation. *Hep Res* 2017 Nov;47(12):1260-1271.
23. Li TH, Liu CW, Lee PC, Huang CC, Lee KC, Hsieh YC, **Yang YY***, Hsieh SL, Lin HC, Tsai CY. Decoy receptor 3 analogous supplement protects steatotic rat liver from ischemia-reperfusion injury. *J Chin Med Assoc*. 2017;80(7):391-400.
24. Li TH, Lee PC, Lee KC, Hsieh YC, Tsai CY, **Yang YY***, Huang SF, Tsai TH, Hsieh SL, Hou MC, Lin

- HC*, Lee SD. Down-regulation of common NFκB-iNOS pathway by chronic Thalidomide treatment improves Hepatopulmonary Syndrome and Muscle Wasting in rats with Biliary Cirrhosis. *Sci Rep* 2016;6:39405.
25. Lee PC, **Yang YY***, Huang CS, Hsieh SL, Lee KC, Hsieh YC, Lee TY, Lin HC. Concomitant inhibition of oxidative stress and angiogenesis by chronic hydrogen-rich saline and N-acetylcysteine treatments improves systemic, splanchnic and hepatic hemodynamics of cirrhotic rats. *Hep Res* 2015;45:578-588.
 26. **Yang YY**, Lee PC, Huang YT, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Lee TY, Lin HC. Involvement of the HIF-1a and Wnt/b-catenin pathways on the protective effects of losartan on fatty liver graft with ischemia/reperfusion injury. *Clin Sci (Lond)* 2014; 126: 163-174.
 27. **Yang YY**, Liu RS, Lee PC, Yeh YC, Huang YT, Lee WP, Lee KC, Hsieh YC, Lee FY, Tan TW, Lin HC. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. *Liver Int* 2014;34: 521-34.
 28. Lin HC, Huang YT, **Yang YY**, Lee PC, Hwang LH, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Liu RS. Beneficial effects of dual VEGFR/FGFR inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. *J Gastroenterol Hepatol* 2014;29:1073-82 (co-first author).
 29. Lee PC, **Yang YY***, Lee WP, Lee KC, Hsieh YC, Lee TY, Lin H. Vitamin D3 treatment has comparative portal hypotensive effects as propranolol by decreasing intrahepatic resistance in cirrhotic rats. *J Gastroenterol Hepatol* 2015;30(3):628-37(corresponding author).
 30. **Yang YY**, Hou MC, Lin MW, Chen PH, Liao WC, Chu CJ, Lin HC*. Combined platelet count with sCD163 and genetic variants optimizes esophageal varices prediction in cirrhotic patients. *J Gastroenterol Hepatol* 2013; 28 (1): 112-21.
 31. Fan WC, Liu WC, Ou SM, Huang CC, Li TH, Lee KC, Huang SF, **Yang YY***, Hsieh YC, Hsieh SL, Hou MC, Lin HC* TLR4/CD14 variants-Related Serologic and Immunologic dys-regulations Predict Severe Sepsis in Febrile De-Compensated Cirrhotic Patients. *PLoS One*. 2016 18;11(11):e0166458.
 32. Li TH, Huang CC, **Yang YY***, Lee KC, Hsieh SL, Hsieh YC, Alan L, Lin HC*, Lee SD, Tsai CY. Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats. *PLoS One*. 2016 28;11(1):e0147212.
 33. PC Lee, **YY Yang***, MC Hou, CS Huang, KC Lee, YW Wang, YC Hsieh, YH Huang, CJ Chu, HC Lin. Benzodiazepine-Associated Hepatic Encephalopathy Significantly Increased Healthcare Utilization and Medical Cost of Chinese Cirrhotic Patients: 7-years Experiences. *Diges Dis Sci* 2014; 59(7):1603-16..
 34. **Yang YY**, Lee TY, Huang YT, Chan CC, Yeh YC, Lee FY, Lee SD, Lin HC. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. *Liver Int* 2012; 32:48-57.
 35. **Yang YY**, Huang YT, Tsai TH, Hou MC, Lee FY, Lee SD, Lin HC*. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH cirrhosis. *Clin Sci (Lond)* 2012; 123: 669-680.
 36. **Yang YY**, Huang YT, Lee TY, Chan CC, Yeh YC, Lee KC, Lin HC*. Rho-Kinase-Dependent Pathway Mediated the Hepatoprotective Effects of Sorafenib for Ischemia/Reperfusion Liver Injury of NASH Rats. *Liver Transplant* 2012;18:1371-83.
 37. **Yang YY**, Lin HC, Lin MW, Chu CJ, Lee FY, Hou MC, Lee SD, Lee WP, Liu TT, Jap TS. Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-

- azotaemic cirrhotic patients with moderate ascites. *Clin Sci* 2011; 121, 509-21.
38. Lee KC, **Yang YY***, Huang YT, Lee FY, Hou MC, Lin HC, Lee SD. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. *Clin Sci* 2010;119(1):45-55 (*co-first author).
 39. **Yang YY**, Lee KC, Huang YT, Lee FY, Chau GY, Loong CC, Lin HC, Lee SD. Inhibition of hepatic tumor necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers. *Liver Int* 2009;29(5):678-85.
 40. **Yang YY**, Huang YT, Lee KC, Lee FY, Lee TY, Hou MC, Lin HC, Lee SD. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis. *Clin Sci* (Lond) 2009;116(1):71-9.
 41. Lee KC, **Yang YY***, Wang YW, Hou MC, Lee FY, Lin HC, Lee SD. Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoidal resistance in cirrhotic patients. *Hep Res* 2008;38:1186-93 (*co-first author).
 42. **Yang YY**, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW, Lee FY, Lee SD. Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis. *Clin Sci* (Lond) 2007;112(10):533-42.
 43. Wang YW, Hou TI, **Yang YY**, Hou MC, Lee PC, Lin HC, Lee FY, Chi CW, Lee SD. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis, *J Clin Gastroenterol* 2007;41:706-12.
 44. **Yang YY**, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW, Lee FY, Lee SD. Role of Ca²⁺-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. *Liver Int* 2007; 7(8):1045-55.
 45. **Yang YY**, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW, Lee FY, Lee SD. Roles of anandamide in the hepatic microcirculation in cirrhotic rats. *Am J Physiol Gastrointest Liver Physiol* 2006;290(2):G328-34.
 46. **Yang YY**, Lin HC, Lee WC, Huang YT, Hou MC, Lee FY, Chang FY, Lee SD. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. *J Gastroenterol Hepatol* 2003;18:1156-61.
 47. **Yang YY**, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, Lee SD. One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. *J Gastroenterol* 2002; 7:194-9.
 48. **Yang YY**, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, Lee SD. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestation. *J Gastroenterol* 2001;36:181-6.
 49. **Yang YY**, Lin HC, Huang YT, Lee TY, Lee WC, Hou MC, Lee FY, Chang FY, Lee SD. Adaptive vasodilatory response after octreotide treatment. *Am J Physiol Gastrointest Liver Physiol* 2001;281:G117-23.